Abstract 3383: Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for translational oncology studies

Abstract Background: Second-generation humanized NOG mice (HIS mice) enable evaluation of immune-oncology mechanisms within a physiologically relevant human immune microenvironment. However, translational interpretation of preclinical efficacy studies requires highly specific and reproducible quantification of human cytokines. To support robust immune monitoring, we co-evaluated a 41-plex humanized mouse cytokine/chemokine Luminex panel for performance across diverse human CD34+ donor sources and multiple HIS NOG model variants. Study Aims/Hypothesis: We hypothesized that the human-specific analytes in the MILLIPLEX® 41-plex humanized mouse multiplex assay would show (i) high specificity for human cytokines with minimal cross-reactivity to host murine analytes, (ii) reproducible quantification across donor-to-donor variation, and (iii) consistent detection sensitivity across advanced HIS NOG models supporting translational oncology applications. Results: Plasma samples were collected from HIS NOG cohorts reconstituted with ≥3 unrelated CD34+ donor pools and representing multiple second-generation humanized platforms. Across all donors and models, human-restricted analytes yielded quantifiable signals above background. Murine-only control samples confirmed negligible cross-reactivity. Inter-assay and intra-assay CVs demonstrated technical reproducibility. Donor-specific cytokine patterns (e.g., Th1/Th2 balance, myeloid-associated chemokines) were preserved across models, indicating biological fidelity rather than assay drift. Baseline cytokine architecture correlated with reconstitution kinetics and human immune cell subset frequencies, supporting biological coherence. Conclusions: These validation data demonstrate that the MILLIPLEX® 41-plex Luminex assay provides reproducible, donor-consistent, and human-specific cytokine quantification in second-generation HIS NOG mice. These data support the assay’s suitability for mechanistic and pharmacodynamic readouts in oncology studies requiring high-resolution human cytokine/chemokine profiling. Reliable multiplex cytokine measurement strengthens the translational bridge between HIS mouse studies and human immuno-oncology responses, enabling improved interpretation of therapeutic mechanisms, biomarkers, and treatment-induced immune modulation. Citation Format: Philip Dubé, Brooke Gilliam, Adam Bell, Nicholas Smith, Janell Richardson, Tina Raeber, Shane Curran, Monika Buczek. Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for translational oncology studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3383.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-3383
Primary Topic
Advanced Biosensing Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 3383: Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for translational oncology studies

Brooke Gilliam, Janell Richardson, Shane A. Curran, Tina Raeber et al.
Cancer Research
Advanced Biosensing Techniques and Applications
article

Abstract 3383: Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for translational oncology studies

Brooke Gilliam, Janell Richardson, Shane A. Curran, Tina Raeber, Philip E. Dubé, Adam C. Bell, Monika Buczek, Nicholas Smith
article en

Abstract

Abstract Background: Second-generation humanized NOG mice (HIS mice) enable evaluation of immune-oncology mechanisms within a physiologically relevant human immune microenvironment. However, translational interpretation of preclinical efficacy studies requires highly specific and reproducible quantification of human cytokines. To support robust immune monitoring, we co-evaluated a 41-plex humanized mouse cytokine/chemokine Luminex panel for performance across diverse human CD34+ donor sources and multiple HIS NOG model variants. Study Aims/Hypothesis: We hypothesized that the human-specific analytes in the MILLIPLEX® 41-plex humanized mouse multiplex assay would show (i) high specificity for human cytokines with minimal cross-reactivity to host murine analytes, (ii) reproducible quantification across donor-to-donor variation, and (iii) consistent detection sensitivity across advanced HIS NOG models supporting translational oncology applications. Results: Plasma samples were collected from HIS NOG cohorts reconstituted with ≥3 unrelated CD34+ donor pools and representing multiple second-generation humanized platforms. Across all donors and models, human-restricted analytes yielded quantifiable signals above background. Murine-only control samples confirmed negligible cross-reactivity. Inter-assay and intra-assay CVs demonstrated technical reproducibility. Donor-specific cytokine patterns (e.g., Th1/Th2 balance, myeloid-associated chemokines) were preserved across models, indicating biological fidelity rather than assay drift. Baseline cytokine architecture correlated with reconstitution kinetics and human immune cell subset frequencies, supporting biological coherence. Conclusions: These validation data demonstrate that the MILLIPLEX® 41-plex Luminex assay provides reproducible, donor-consistent, and human-specific cytokine quantification in second-generation HIS NOG mice. These data support the assay’s suitability for mechanistic and pharmacodynamic readouts in oncology studies requiring high-resolution human cytokine/chemokine profiling. Reliable multiplex cytokine measurement strengthens the translational bridge between HIS mouse studies and human immuno-oncology responses, enabling improved interpretation of therapeutic mechanisms, biomarkers, and treatment-induced immune modulation. Citation Format: Philip Dubé, Brooke Gilliam, Adam Bell, Nicholas Smith, Janell Richardson, Tina Raeber, Shane Curran, Monika Buczek. Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for translational oncology studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3383.

Cancer ResearchVol. 86(7_Supplement)
Line Corporation (Japan) (JP), Taconic (United States) (US)
Openalex Percentile: Top 7%
Advanced Biosensing Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.